Mammography screening intervals may affect breast cancer prognosis

In its earliest stages, breast cancer is confined to the breast and can be treated by surgically removing the cancer cells. As the disease progresses, breast cancer cells may spread to the lymph nodes and then to other areas of the body.

“On its pathway to other places in the body, the first place breast cancer typically drains into before metastasizing is the lymph nodes,” said Lilian Wang, M.D., assistant professor of radiology at Northwestern University/Feinberg School of Medicine in Chicago, Ill. “When breast cancer has spread into the lymph nodes, the patient is often treated both locally and systemically, with either hormone therapy, chemotherapy, trastuzumab or some combination of these therapies.”

Historically, healthcare organizations, such as RSNA and the American Cancer Society (ACS), have recommended annual screening with mammography for women beginning at age 40. However, in 2009, the United States Preventive Services Task Force (USPSTF) announced a controversial new recommendation for biennial screening for women between the ages of 50 and 74.

“Our study looks at what would happen if the revised guidelines issued by USPSTF were followed by women,” Dr. Wang said.

The retrospective study, conducted at Northwestern Memorial Hospital, included 332 women with breast cancer identified by screening mammography between 2007 and 2010. The women were divided into one of three groups, based on the length of time between their screening mammography exams: less than 1.5 years, 1.5 to three years and more than three years. There were 207, 73 and 52 patients in each category, respectively.

Controlling for age, breast density, high-risk status and a family history of breast cancer, the researchers determined that women in the less than 1.5-year interval group had the lowest lymph node positivity rate at 8.7 percent. The rate of lymph node involvement was significantly higher in the 1.5- to three-year and over three-year interval groups at 20.5 percent and 15.4 percent, respectively.

“Our study shows that screening mammography performed at an interval of less than 1.5 years reduces the rate of lymph node positivity, thereby improving patient prognosis,” Dr. Wang said. “We should be following the guidelines of the American Cancer Society and other organizations, recommending that women undergo annual screening mammography beginning at age 40.”

Co-authors are Ellen B. Mendelson, M.D., Paula M. Grabler, M.D., Riti Mahadevia, B.A., and Laura Billadello, M.D.

Note: Copies of RSNA 2013 news releases and electronic images will be available online at RSNA.org/press13 beginning Monday, Dec. 2.

RSNA is an association of more than 53,000 radiologists, radiation oncologists, medical physicists and related scientists, promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Ill. (RSNA.org)

For patient-friendly information on mammography, visit RadiologyInfo.org.

Media Contact

Linda Brooks EurekAlert!

More Information:

http://www.rsna.org

All latest news from the category: Studies and Analyses

innovations-report maintains a wealth of in-depth studies and analyses from a variety of subject areas including business and finance, medicine and pharmacology, ecology and the environment, energy, communications and media, transportation, work, family and leisure.

Back to home

Comments (0)

Write a comment

Newest articles

Nerve cells of blind mice retain their visual function

Nerve cells in the retina were analysed at TU Wien (Vienna) using microelectrodes. They show astonishingly stable behavior – good news for retina implants. The retina is often referred to…

State-wide center for quantum science

Karlsruhe Institute of Technology joins IQST as a new partner. The mission of IQST is to further our understanding of nature and develop innovative technologies based on quantum science by…

Newly designed nanomaterial

…shows promise as antimicrobial agent. Rice scientists develop nanocrystals that kill bacteria under visible light. Newly developed halide perovskite nanocrystals (HPNCs) show potential as antimicrobial agents that are stable, effective…